Anti-PD-L1 antibodies and uses thereof

US11220546B2 · kind B2 · utility

Assignee

• I-MAB BIOPHARMA US LIMITED · US

Inventors

• Lei Fang · Katy, US
• Yongqiang Wang · Shanghai, CN
• Zhengyi Wang · Shanghai, CN
• Bingshi Guo · Shanghai, CN
• Jingwu Zang · Shanghai, CN

Key dates

• Filing date: Mar 29, 2019
• Grant date: Jan 11, 2022
• Expiry date: Sep 11, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 116, a VH CDR3 of SEQ ID NO: 117, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.